Karolien Castermans

2.6k total citations · 1 hit paper
31 papers, 2.1k citations indexed

About

Karolien Castermans is a scholar working on Molecular Biology, Oncology and Ophthalmology. According to data from OpenAlex, Karolien Castermans has authored 31 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Ophthalmology. Recurrent topics in Karolien Castermans's work include Angiogenesis and VEGF in Cancer (12 papers), Glaucoma and retinal disorders (7 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Karolien Castermans is often cited by papers focused on Angiogenesis and VEGF in Cancer (12 papers), Glaucoma and retinal disorders (7 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Karolien Castermans collaborates with scholars based in Belgium, Netherlands and United States. Karolien Castermans's co-authors include Arjan W. Griffioen, Mirjam G.A. oude Egbrink, Judy R. van Beijnum, Sébastien P. Tabruyn, Ruud P.M. Dings, Kevin H. Mayo, Ingrid Struman, Joseph Martial, Ludovic Malvaux and Daisy W.J. van der Schaft and has published in prestigious journals such as Journal of Clinical Investigation, Blood and The Journal of Immunology.

In The Last Decade

Karolien Castermans

31 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy

2013 380 citations Julie Halkein, Sébastien P. Tabruyn et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Karolien Castermans

Since Specialization

Citations

This map shows the geographic impact of Karolien Castermans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karolien Castermans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karolien Castermans more than expected).

Fields of papers citing papers by Karolien Castermans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karolien Castermans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karolien Castermans. The network helps show where Karolien Castermans may publish in the future.

Co-authorship network of co-authors of Karolien Castermans

This figure shows the co-authorship network connecting the top 25 collaborators of Karolien Castermans. A scholar is included among the top collaborators of Karolien Castermans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karolien Castermans. Karolien Castermans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model 2022 ·Cellular and Molecular Life Sciences ·Tom Van Loy, Steven De Jonghe, Karolien Castermans, (unknown), Reinout Stoop, Lars Verschuren, Matthias Versele, Patrick Chaltin, Aernout Luttun, Dominique Schols	4
2	Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase Inhibitor 2017 ·Gastroenterology ·Tom Holvoet, Sarah Devriese, Karolien Castermans, Sandro Boland, Dirk Leysen, Yves‐Paul Vandewynckel, Lindsey Devisscher, Lien Van den Bossche, Sophie Van Welden, Mélissa Dullaers, Roosmarijn E. Vandenbroucke, Riet De Rycke, Karel Geboes, Arnaud Bourin, Olivier Defert, Pieter Hindryckx, Martine De Vos, Debby Laukens	110
3	Rho kinase inhibitor AMA0526 improves surgical outcome in a rabbit model of glaucoma filtration surgery 2015 ·Progress in brain research ·Sarah Van de Velde, Tine Van Bergen, Evelien Vandewalle, (unknown), Karolien Castermans, Lieve Moons, Ingeborg Stalmans	38
4	Inhibition of Rho-Associated Kinase Prevents Pathological Wound Healing and Neovascularization After Corneal Trauma 2015 ·Cornea ·(unknown), Tine Van Bergen, Karolien Castermans, (unknown), Evelien Vandewalle, Jean–Marie Stassen, Lieve Moons, Ingeborg Stalmans	20
5	The Effect of AMA0428, a Novel and Potent ROCK Inhibitor, in a Model of Neovascular Age-Related Macular Degeneration 2015 ·Investigative Ophthalmology & Visual Science ·Karen Hollanders, Tine Van Bergen, Nadège Kindt, Karolien Castermans, Dirk Leysen, Evelien Vandewalle, Lieve Moons, Ingeborg Stalmans	43
6	Design, synthesis and biological characterization of selective LIMK inhibitors 2015 ·Bioorganic & Medicinal Chemistry Letters ·Sandro Boland, Arnaud Bourin, Jo Alen, (unknown), (unknown), Karolien Castermans, (unknown), (unknown), (unknown), (unknown), (unknown), Sarah Van de Velde, Olivier Defert	23
7	Novel Roflumilast analogs as soft PDE4 inhibitors 2014 ·Bioorganic & Medicinal Chemistry Letters ·Sandro Boland, Jo Alen, Arnaud Bourin, Karolien Castermans, (unknown), (unknown), (unknown), Dirk Leysen, Olivier Defert	30
8	3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Sandro Boland, Olivier Defert, Jo Alen, Arnaud Bourin, Karolien Castermans, (unknown), (unknown), (unknown), Sarah Van de Velde, Ingeborg Stalmans, Dirk Leysen	26
9	MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy breakdown → 2013 ·Journal of Clinical Investigation ·Julie Halkein, Sébastien P. Tabruyn, Melanie Ricke‐Hoch, Aiden Haghikia, Ngoc-Quynh-Nhu Nguyen, Michaela Scherr, Karolien Castermans, Ludovic Malvaux, Vincent Lambert, Marc Thiry, Karen Sliwa, Agnès Noël, Joseph Martial, Denise Hilfiker‐Kleiner, Ingrid Struman	380
10	In Vitro Hydrolysis of Latanoprost by Human Ocular Tissues 2012 ·Investigative Ophthalmology & Visual Science ·(unknown), Joseph Rager, (unknown), Ismael J. Hidalgo, Karolien Castermans, Olivier Defert, Sandro Boland	2
11	Enhancement of T-cell–Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer 2011 ·Clinical Cancer Research ·Ruud P.M. Dings, Kieng B. Vang, Karolien Castermans, Flavia E. Popescu, Yan Zhang, Mirjam G.A. oude Egbrink, Matthew F. Mescher, Michael A. Farrar, Arjan W. Griffioen, Kevin H. Mayo	59
12	Small-Molecule Inhibitors of Vascular Adhesion Protein-1 Reduce the Accumulation of Myeloid Cells into Tumors and Attenuate Tumor Growth in Mice 2010 ·The Journal of Immunology ·Fumiko Marttila‐Ichihara, Karolien Castermans, Kaisa Auvinen, Mirjam G.A. oude Egbrink, Sirpa Jalkanen, Arjan W. Griffioen, Marko Salmi	32
13	Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis 2010 ·Molecular Cancer ·Céline Sabatel, Anne Cornet, Sébastien P. Tabruyn, Ludovic Malvaux, Karolien Castermans, Joseph Martial, Ingrid Struman	22
14	Molecular imaging of tumor angiogenesis using αvβ3-integrin targeted multimodal quantum dots 2008 ·Angiogenesis ·Willem J. M. Mulder, Karolien Castermans, Judy R. van Beijnum, Mirjam G.A. oude Egbrink, P. Chin, Zahi A. Fayad, Clemens W.G.M. Löwik, Eric L. Kaijzel, Ivo Que, Gert Storm, Gustav J. Strijkers, Arjan W. Griffioen, Klaas Nicolay	109
15	A transgenic Tie2-GFP athymic mouse model; a tool for vascular biology in xenograft tumors 2008 ·Biochemical and Biophysical Research Communications ·Femke Hillen, Eric L. Kaijzel, Karolien Castermans, Mirjam G.A. oude Egbrink, Clemens W.G.M. Löwik, Arjan W. Griffioen	30
16	Isolation of endothelial cells from fresh tissues 2008 ·Nature Protocols ·Judy R. van Beijnum, Mat Rousch, Karolien Castermans, Edith van der Linden, Arjan W. Griffioen	153
17	Tumor blood vessels, a difficult hurdle for infiltrating leukocytes 2007 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Karolien Castermans, Arjan W. Griffioen	41
18	Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications 2006 ·Cancer Research ·Debby M.E.I. Hellebrekers, Karolien Castermans, Emmanuelle Viré, Ruud P.M. Dings, Nicole Hoebers, Kevin H. Mayo, Mirjam G.A. oude Egbrink, Grietje Molema, François Fuks, Manon van Engeland, Arjan W. Griffioen	129
19	Effects of radiotherapy and chemotherapy on angiogenesis and leukocyte infiltration in rectal cancer 2006 ·International Journal of Radiation OncologyBiologyPhysics ·Coen I.M. Baeten, (unknown), Karolien Castermans, (unknown), Femke Hillen, Bradly G. Wouters, H.F.P. Hillen, Arjan W. Griffioen, (unknown), (unknown)	40
20	Tumor Cell Plasticity in Ewing Sarcoma, an Alternative Circulatory System Stimulated by Hypoxia 2005 ·Cancer Research ·Daisy W.J. van der Schaft, Femke Hillen, Patrick Pauwels, Dawn A. Kirschmann, Karolien Castermans, Mirjam G.A. oude Egbrink, Maxine Tran, Raf Sciot, Esther Hauben, Pancras C.W. Hogendoorn, Olivier Delattre, Patrick H. Maxwell, Mary J.C. Hendrix, Arjan W. Griffioen	168

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact